# A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

> **NCT07629726** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** KK2430

## Key facts

- **NCT ID:** NCT07629726
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-04
- **Final completion:** 2027-10
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629726, "A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07629726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*